FDA Approves MEFENAMIC ACID — Lupin Pharmaceuticals, Inc.

NEW YORK (Thomson Financial) - Lupin Pharmaceuticals Inc. announced Thursday that the FDA has approved its generic version of mefenamic acid tablets, potentially expanding access to this nonsteroidal anti-inflammatory drug just a few weeks after competitors began launching copycat formulations. The approval is expected to intensify competition in the pain relief market, creating intense pricing pressure and challenging the remaining incremental revenue for brand-name players in the space.